Increased Clearance of Propranolol in Thyrotoxicosis

  1. JOHN FEELY, M. D.;
  2. IAN H. STEVENSON, Ph.D.; and
  3. JAMES CROOKS, M.D.
  1. Dundee, Scotland

    Abstract

    The pharmacokinetics of oral propranolol were studied during chronic treatment in six patients when thyrotoxic and again when euthyroid. The mean total plasma propranolol steady-state concentration was 42% lower when the patients were thyrotoxic. After treatment of thyrotoxicosis there was a fall (p < 0.05) in the oral clearance of both total (4.2 ± 0.6 to 2.7 ± 0.4 L/min, mean ± SEM) and free (30.5 ± 4.7 to 25.5 ± 4.1 L/min) propranolol although the half-life of propranolol did not change significantly. The free fraction of propranolol was higher (p < 0.05) in the thyrotoxic (14.2% ± 1.3%) than in the euthyroid (11.4% ± 0.8%) state. These results suggest that the pharmacokinetics of propranolol are significantly altered in thyrotoxicosis.

    Article and Author Information

    • ▸From the Department of Pharmacology and Therapeutics, University of Dundee and Ninewells Hospital and Medical School; Dundee, Scotland.

    • ▸Requests for reprints should be addressed to John Feely, M.D.; Department of Pharmacology and Therapeutics, Ninewells Hospital; Dundee, DD1 9SY, Scotland.

    « Previous | Next Article »Table of Contents